Advances in Chronic Lymphocytic Leukemia Care:
A Focus on Empowering the Multidisciplinary Community-Based Team

Faculty

Erin Fahey-Harrison, PA-C, NP, PA
Sr. Instructor, Medicine-Hematology
University of Colorado Hospital
Aurora, CO

Program Overview

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) management demands a patient-centered approach, focusing on symptomatic patients or those at high risk of progression. This program will cover the latest risk classification criteria and clinical guidelines, emphasizing the transition from chemo-immunotherapy to targeted therapies like Bruton kinase inhibitors (BTKi), anti-CD20 monoclonal antibodies, and BCL2 inhibitors.

Given the incurable nature of CLL/SLL, patients often require multiple treatments, each with specific benefits and risks. The program will highlight evidence-based practices and a multidisciplinary approach to enhance patient outcomes, supported by case scenarios demonstrating the application of emerging therapies in clinical practice.

Target Audience

This program is intended for community-based medical hematologists/oncologists, advanced practice providers, nurses, pharmacists, and other healthcare professionals involved in the treatment of patients with CLL. 

Learning Objectives

Upon completion of this activity, the participant should be able to:

  • DISCUSS therapeutic approaches for treatment-naive and relapsed/refractory CLL/SLL. 
  • SUMMARIZE the differences in selectivity, binding, efficacy, and adverse event profiles of agents with a similar molecular target used to treat CLL/SLL.  
  • EVALUATE the evolving role of current and emerging therapeutics for CLL/SLL. 
  • DESCRIBE how to manage treatment-related symptoms in patients with CLL/SLL.  
  • OUTLINE multidisciplinary management plans for patients with CLL/SLL to optimize quality of life and address racial and age-related disparities in care. 

Educational Activities

Social Media Broadcasts
Webcast

Roundtable Webcast

Credit Amount: 1.0
Credit Type: AMA, ANCC
Release: TBD

SOCIAL MEDIA BROADCAST ONE

Credit Amount: 0.25
Credit Type: AMA, ANCC
Release: TBD
Expiration: TBD

SOCIAL MEDIA BROADCAST TWO

Credit Amount: 0.25
Credit Type: AMA, ANCC
Release: TBD
Expiration: TBD

This activity is jointly provided by Global Education Group and Iridium Continuing Education.

SUPPORTER ACKNOWLEDGEMENT
This educational activity is supported by independent educational grants from Janssen Biotech, Inc, administered by Janssen Scientific Affairs, LLC and AbbVie Inc.

Maximum Credit Amount: 1.50
Credit Type: AMA
Release: TBD
Expiration: TBD